Climb Bio, Inc. Share Price & Technical Analysis
CLYM · $11.22 (+2.00%)
Healthcare / Biotechnology
$11.22
+2.00%
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary mem…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
24% return in May, -2% avg return in past 3 year May month.
128% return in 2026, 49% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 10% | 64% | 0% | 31% | 24% | – | – | – | – | – | – | – | 128% |
| 25 | 6% | -21% | -20% | 8% | -8% | 0% | 17% | 57% | -9% | 0% | -5% | 111% | 135% |
| 24 | -4% | 4% | -4% | 163% | 13% | -8% | 17% | -16% | -26% | -24% | -18% | -45% | 53% |
| 23 | -8% | 0% | -17% | 11% | -12% | -3% | -10% | 0% | -4% | 0% | 0% | 4% | -40% |
| 22 | -13% | -1% | -5% | -61% | 23% | -21% | -3% | -3% | 7% | 3% | -24% | 42% | -56% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Strong
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$629.29M
P/E ratio
—
52W high
$12.48
52W low
$1.16
Volume
2,87,630
Beta
0.03
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Climb Bio, Inc. share price today?
- Climb Bio, Inc. (CLYM) last traded around $11.22 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CLYM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CLYM. Download the app for real-time alerts.
- How can I analyze Climb Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.